These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 6189910)

  • 1. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
    Toffaletti DL; Darrow TL; Scott DW
    J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA; Walker MC; Phillips-Quagliata JM
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma.
    Kim BS
    J Immunol; 1979 Aug; 123(2):739-44. PubMed ID: 88483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target determinants for F1 hybrid anti-parental H-2d cell-mediated lympholysis: self antigens controlled by the D end.
    Nakamura I; Nakano K; Cudkowicz G
    J Immunol; 1983 May; 130(5):2429-33. PubMed ID: 6187857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a T suppressor cell-inducing antigenic determinant shared by ADJ-PC-5 plasmacytoma and syngeneic BALB/c spleen cells.
    Kloke O; Haubeck HD; Kölsch E
    Eur J Immunol; 1986 Jun; 16(6):659-64. PubMed ID: 2424769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR
    J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
    Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
    Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to somatic cell hybrids between ultraviolet radiation-induced regressor and spontaneous progressor C3H mouse tumor cells.
    Chen PW; Kaba DS; Ananthaswamy HN
    Cancer Res; 1990 Mar; 50(5):1544-9. PubMed ID: 2137370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.
    LeGrue SJ; Ananthaswamy HN; Simcik WJ
    Cancer Res; 1989 Sep; 49(17):4747-51. PubMed ID: 2474372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibition of hybrid resistance in F1 hybrid mice pretreated with parent-strain spleen cells. II. Evidence for an Hh-1 antigen-specific tolerization.
    Kosmatopoulos K; Scott-Algara D; Halle-Pannenko O
    J Immunol; 1988 Nov; 141(10):3285-92. PubMed ID: 2460528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of cytotoxic T lymphocytes in vitro. VII. Suppressive effect of irradiated MLC cells on CTL response.
    Fitch FW; Engers HD; Cerottini JC; Bruner KT
    J Immunol; 1976 Mar; 116(3):716-23. PubMed ID: 56399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens.
    Kedar E; Bonavida B
    J Immunol; 1975 Nov; 115(5):1301-8. PubMed ID: 51889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immunity to murine plasma cell tumors. V. Genetic control of the in vitro cytotoxic T-cell response to plasma cell tumor-associated antigens of NZB mice.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1980 Aug; 65(2):431-40. PubMed ID: 6967529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary in vitro generation of CTL specific for MM antigen by stimulation with somatic tumor hybrid, but not with parental tumor cells.
    Ishikawa S; Tachibana T
    J Immunol; 1983 Oct; 131(4):2059-63. PubMed ID: 6194225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.